Key factors
sym | NAOV |
exch | US |
MCap | 2088.26K |
Beta | 1.275 |
EPS | -2.12 |
Div date | 0000-00-00 |
Yesterday
sym | NAOV |
exch | US |
close | 0.758 |
50 Day MA | 0.952 |
200 Day MA | 1.547 |
52 Week High | 4.34 |
52 Week Low | 0.7 |
Target Price | 10.5 |
Market Cap Mln | 2.088 |
Share statistics
Shares Outstanding | 2784.35K |
Shares Float | 2542.84K |
Percent Institutions | 12.00 |
PercentInsiders | 0.421 |
SharesShort | 2714.0 |
Short Ratio | 0.08 |
Shares Short Prior Month | 7296.0 |
Short Percent | 0.130 |
Income
Revenue TTM | 2283.0K |
Revenue Per Share TTM | 1.304 |
Quarterly Revenue Growth YOY | 372.19 |
Gross Profit TTM | 167.0K |
EBITDA | -3075.0K |
Diluted Eps TTM | -2.12 |
earning
Operating Margin TTM | -0.29 |
Earnings Share | -2.12 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 2023-02-09 |
Last Split Factor | 1:20 |
business
Enterprise Value Ebitda | 0.327 |
Enterprise Value Revenue | 1.116 |
Book Value /share | 1.949 |
Price Book MRQ | 0.530 |
Price Sales TTM | 0.926 |
ProfitMargin | -1.62 |
ReturnOnAssetsTTM | -0.30 |
ReturnOnEquityTTM | -1.02 |
Sector
Gic Group | Health Care Equipment & Services |
Gic Industry | Health Care Equipment & Supplies |
Gic Sector | Health Care |
Gic Sub Industry | Health Care Equipment |
Industry | Medical Devices |
Sector | Healthcare |
Codes
ISIN | US63008J1088 |
CIK | 1326706 |
Code | NAOV |
CUSIP | 63008J207 |
Employer Id Number | 01-0801232 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 10.0 |
IPODate | 2017-06-27 |
International Domestic | Domestic |
MostRecent Quarter | 2024-03-31 |
Contact
Name | NanoVibronix Inc |
Address | 525 Executive Boulevard, Elmsford, NY, United States, 10523 |
Country Name | USA |
Phone | 914 233 3004 |
Web URL | https://www.nanovibronix.com |
Logo URL | /img/logos/US/NAOV.png |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.